Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
NCT ID NCT07652736
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes like tumor response. The goal is to understand how the drug performs outside of strict clinical trial settings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab
What this could lead to
If successful, this study could provide real-world evidence on how well tislelizumab works outside of controlled trials, helping doctors make better treatment decisions for lung cancer patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences and real-world variability. It does not test a new treatment or prove effectiveness definitively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General de Segovia
RECRUITINGSegovia, Spain